Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136171 · ClinicalTrials.gov registry record · Phase 3
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
A Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), sponsored by Ionis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 1,438
- Enrollment target
- 20
- Study locations
NCT04136171 is a Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) that is active but no longer recruiting, run by Ionis Pharmaceuticals. The registered enrollment target is 1,438 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT04136171, a Phase 3 study of Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), is active but no longer recruiting, sponsored by Ionis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,438 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eplontersen
Study Locations (20)
California
- Altman Clinical and Translational Research Institute Center for Clinical Research - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California, San Francisco (UCSF) - Medical Center - San Francisco
- Stanford Hospital - Stanford
Illinois
- Northwestern University - Chicago
- The University of Chicago Medical Center - Chicago
- Loyola University Medical Center - Maywood
Louisiana
- Louisiana State University Health Sciences Center - New Orleans
- Tulane University Heart and Vascular Institute - New Orleans
- Ochsner Health System - New Orleans
District of Columbia
- MedStar Washington Hospital Center - Washington D.C.
- The George Washington Medical Faculty Associates - Foggy Bottom North Pavilion - Washington D.C.
Georgia
- Emory Heart and Vascular Center - Emory Clifton Campus - Atlanta
- Piedmont Heart of Fayetteville - Fayetteville
Arizona
- Mayo Clinic - Arizona - Phoenix
Colorado
- University of Colorado Hospital - Anschutz Medical Campus - Aurora
Florida
- Cleveland Clinic Florida - Weston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,438 participants |
| Start Date | 2020-03-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136171
The ClinicalTrials.gov registry entry for NCT04136171 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04136171 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04136171 about?
NCT04136171 is a clinical study titled "CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)". To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC).
What is the current status of trial NCT04136171?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,438 participants. The study started on 2020-03-13. Estimated completion is 2026-08.
What conditions does trial NCT04136171 study?
This clinical trial studies the following conditions: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM).
What interventions are being tested in trial NCT04136171?
The interventions under investigation include: Placebo (DRUG), Eplontersen (DRUG).
Who is sponsoring clinical trial NCT04136171?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04136171 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.